A. Prakash

发表

A randomized, placebo-controlled study of duloxetine for the treatment of children and adolescents with generalized anxiety disorder.

R. Findling, J. Strawn, Qi Zhang, 2015, Journal of the American Academy of Child and Adolescent Psychiatry.

The relationship between functional outcomes and the treatment of anxious and painful somatic symptoms in patients with generalized anxiety disorder*

D. Sheehan, J. Russell, C. Mallinckrodt, 2008 .

A double-blind efficacy and safety study of duloxetine flexible dosing in children and adolescents with major depressive disorder.

J. March, Qi Zhang, G. Emslie, 2014, Journal of child and adolescent psychopharmacology.

An Open-label Study of Duloxetine for the Treatment of Major Depressive Disorder: Comparison of Switching Versus Initiating Treatment Approaches

M. Fava, C. Mallinckrodt, J. Martinez, 2005, Journal of clinical psychopharmacology.

Fluoxetine versus placebo in posttraumatic stress disorder

H. Zhang, E. Brown, F. Martényi, 2001, European Neuropsychopharmacology.

A qualitative interview study to explore adolescents’ experience of alopecia areata and the content validity of sign/symptom patient‐reported outcome measures

R. Burge, E. Edson-Heredia, B. King, 2021, The British journal of dermatology.

Assessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan disability scale

D. Sheehan, K. Harnett-Sheehan, A. Prakash, 2011, International clinical psychopharmacology.

JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies

D. Foell, S. Holland, S. Paul, 2018, The Journal of clinical investigation.

Duloxetine for the treatment of major depressive disorder: a closer look at efficacy and safety data across the approved dose range.

C. Mallinckrodt, J. Watkin, A. Andorn, 2006, Journal of psychiatric research.

Acute and longer-term safety results from a pooled analysis of duloxetine studies for the treatment of children and adolescents with major depressive disorder.

J. March, Qi Zhang, G. Emslie, 2015, Journal of child and adolescent psychopharmacology.

ORIGINAL RESEARCH—PSYCHOLOGY: Changes in Sexual Functioning Associated with Duloxetine, Escitalopram, and Placebo in the Treatment of Patients with Major Depressive Disorder

S. Kornstein, C. Mallinckrodt, A. Clayton, 2007 .

The clinical importance of changes in the 0 to 10 numeric rating scale for worst, least, and average pain intensity: analyses of data from clinical trials of duloxetine in pain disorders.

J. Farrar, Y. Pritchett, A. Chappell, 2010, The journal of pain : official journal of the American Pain Society.

Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder.

S. Kornstein, C. Mallinckrodt, A. Clayton, 2007, The journal of sexual medicine.

An open-label safety and pharmacokinetics study of duloxetine in pediatric patients with major depression.

R. Tamura, J. March, C. Kratochvil, 2012, Journal of child and adolescent psychopharmacology.

A double-blind efficacy and safety study of duloxetine fixed doses in children and adolescents with major depressive disorder.

J. March, Qi Zhang, G. Emslie, 2014, Journal of child and adolescent psychopharmacology.

Fluoxetine v. placebo in prevention of relapse in post-traumatic stress disorder

E. Brown, F. Martényi, S. Koke, 2002, British Journal of Psychiatry.

Simple options for improving signal detection in antidepressant clinical trials.

M. Detke, C. Mallinckrodt, D. Faries, 2007, Psychopharmacology bulletin.

Pharmacokinetics, Pharmacodynamics, and Proposed Dosing of the Oral JAK1 and JAK2 Inhibitor Baricitinib in Pediatric and Young Adult CANDLE and SAVI Patients

M. Gadina, Y. Huang, Paul G. Wakim, 2018, Clinical pharmacology and therapeutics.

Fluoxetine may prevent relapse in post traumatic stress disorder

A. Prakash, 2003 .

Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder*

L. Arnold, C. Mallinckrodt, T. Pigott, 2007, Current medical research and opinion.

Early symptom change prediction of remission in depression treatment.

M. Katz, J. Houston, A. Meyers, 2009, Psychopharmacology bulletin.

Comparisons of the Efficacy and Safety of Duloxetine for the Treatment of Fibromyalgia in Patients With Versus Without Major Depressive Disorder

L. Arnold, D. Kajdasz, J. Hudson, 2009, The Clinical journal of pain.

Differential Antidepressant Symptom Efficacy: Placebo-Controlled Comparisons of Duloxetine and SSRIs (Fluoxetine, Paroxetine, Escitalopram)

M. Fava, M. Detke, C. Mallinckrodt, 2007, Neuropsychobiology.

Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study*

A. Nierenberg, J. Greist, G. Tollefson, 2007, Current medical research and opinion.

Assessment of depressive symptoms and functional outcomes in patients with major depressive disorder treated with duloxetine versus placebo: primary outcomes from two trials conducted under the same protocol

M. Thase, L. Marangell, S. Kornstein, 2012, Human psychopharmacology.

The relationship between functional outcomes and the treatment of anxious and painful somatic symptoms in patients with generalized anxiety disorder.

D. Sheehan, J. Russell, C. Mallinckrodt, 2008, Current medical research and opinion.

Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation

C. Mallinckrodt, J. Watkin, W. P. Carter, 2007, Depression and anxiety.

Safety and tolerability of duloxetine treatment of diabetic peripheral neuropathic pain between patients with and without cardiovascular conditions.

J. Wernicke, D. Kajdasz, J. Houston, 2009, Journal of diabetes and its complications.

Microsampling in pediatric studies: pharmacokinetic sampling for baricitinib (Olumiant™) in global pediatric studies.

Lisa B Lee, S. Keller, E. Wickremsinhe, 2023, Bioanalysis.

The impact of analytic method on interpretation of outcomes in longitudinal clinical trials

C. Mallinckrodt, R. Risser, A. Prakash, 2008, International journal of clinical practice.

Early symptom change prediction of remission in depression treatment.

M. Katz, J. Houston, A. Meyers, 2009, Psychopharmacology bulletin.